|Security||BSFT / BroadSoft, Inc. (11133B409)|
|Common Shares Outstanding||31,649,386 shares (as of 2017-09-30)|
Stock Insider Trading (from SEC Form 4)
BroadSoft, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
BSFT / BroadSoft, Inc. insiders include DIPALMA DINO Magelli Paul, Maine Douglas L, Tholen James Albert, Tessler Michael, Geisse Andrew M, SAGE GAVIN EVA, GAVIN JOHN J JR, Dourgarian Dennis, and Dietze Jane A, Markley John D. Jr., Hoffpauir Scott D., Bernardi David, BEHBEHANI TAHER G., .
GAVIN JOHN J JR
Dietze Jane A
SAGE GAVIN EVA
Maine Douglas L
Geisse Andrew M
Markley John D. Jr.
BEHBEHANI TAHER G.
Hoffpauir Scott D.
Tholen James Albert
Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.
|4||Tholen James Albert||D||D||55.00||-109,440||0|
|4||Tholen James Albert||A||D||34,983||109,440|
|4||Hoffpauir Scott D. By The Scott D. Hoffpauir 2000 Family Irrevocable Trust||D||I||55.00||-16,666||0|
|4||Hoffpauir Scott D.||D||D||55.00||-112,974||0|
|4||Hoffpauir Scott D.||A||D||34,983||112,974|
|4||BEHBEHANI TAHER G.||D||D||55.00||-68,573||0|
|4||BEHBEHANI TAHER G.||A||D||7,301||68,573|
|4||Markley John D. Jr.||D||D||55.00||-22,089||0|
|4||Markley John D. Jr.||G||D||-750||22,089|
|4||Geisse Andrew M||D||D||55.00||-11,689||0|
|4||Maine Douglas L||D||D||55.00||-52,798||0|
|4||SAGE GAVIN EVA||D||D||55.00||-5,022||0|
|4||Dietze Jane A||D||D||55.00||-5,640||0|
|4||GAVIN JOHN J JR||D||D||55.00||-17,321||0|
|4||BEHBEHANI TAHER G.||F||D||55.00||-1,120||61,272|
|4||Hoffpauir Scott D.||S||X||D||54.96||-4,448||94,657||5,202,349|
|4||Hoffpauir Scott D.||F||D||54.85||-1,506||99,105|
|4||Tholen James Albert||F||D||54.85||-1,414||74,457|
|4||BEHBEHANI TAHER G.||F||D||54.85||-983||62,392|
|4||Hoffpauir Scott D.||S||X||D||54.66||-4,448||100,611||5,499,397|
|4||Hoffpauir Scott D.||F||D||54.80||-1,815||105,059|
|4||Tholen James Albert||F||D||54.80||-1,700||75,871|
|4||BEHBEHANI TAHER G.||F||D||54.80||-1,119||63,375|
|4||Hoffpauir Scott D.||S||X||D||54.57||-4,448||106,874||5,832,114|
|4||BEHBEHANI TAHER G.||F||D||53.90||-1,560||64,494|
|4||Hoffpauir Scott D.||S||X||D||52.89||-4,448||111,322||5,887,821|
|4||Hoffpauir Scott D.||F||D||53.15||-1,950||115,770|
|4||Tholen James Albert||F||D||53.15||-1,822||77,571|
|4||BEHBEHANI TAHER G.||F||D||53.15||-1,107||66,054|
|4||Hoffpauir Scott D.||S||X||D||51.50||-4,448||117,720||6,062,580|
|4||Hoffpauir Scott D.||S||X||D||50.00||-8,896||122,168||6,108,400|
|4||Hoffpauir Scott D.||S||X||D||48.00||-13,344||131,064||6,291,072|
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET